Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy

ResearchWorks/Manakin Repository

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics

Related Information

Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy

Show simple item record

dc.contributor.author Marra, Christina M. en_US
dc.contributor.author Maxwell, Clare L. en_US
dc.contributor.author Collier, Ann C. en_US
dc.contributor.author Robertson, Kevin R. en_US
dc.contributor.author Imrie, Allison en_US
dc.date.accessioned 2010-04-21T15:57:29Z
dc.date.available 2010-04-21T15:57:29Z
dc.date.issued 2007 en_US
dc.identifier.citation Marra C, Maxwell C, Collier A, Robertson K, Imrie A. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infectious Diseases. 2007;7(1):37. en_US
dc.identifier.other 10.1186/1471-2334-7-37 en_US
dc.identifier.uri http://www.biomedcentral.com/1471-2334/7/37 en_US
dc.identifier.uri http://hdl.handle.net/1773/15786
dc.description.abstract Background: Cerebrospinal fluid (CSF) pleocytosis may be seen in asymptomatic HIV-infected individuals. This finding complicates interpretation of CSF abnormalities when such individuals are evaluated for other central nervous system infections. The goal of this study was to determine the relationship between CSF pleocytosis, central nervous system (CNS) antiretroviral penetration, adherence to antiretroviral medication regimens, neurological symptoms and performance on neuropsychological tests. Methods: Clinically stable HIV-infected individuals at any peripheral blood CD4+ T cell count or any plasma viral load were asked to attend study visits at entry and every 6 months thereafter for at least one year. At each visit, they underwent a standardized neurological and medication history; neurological examination; a brief neuropsychological test battery: venipuncture; lumbar puncture; and assessment of medication adherence. Generalized estimating equations (GEE) were used to assess the relationships between CSF pleocytosis and other variables. Results: CSF pleocytosis was independently and significantly related to lack of current antiretroviral use (OR 5.9, 95% CI 1.8-18.6, p = 0.003), CD4 count >200/ul (OR 23.4, 95% CI 3.1-177.3, p = 0.002) and detectable plasma HIV RNA (OR 3.3, 95% CI 1.1-9.4, p = 0.03). At visits where antiretrovirals were used, and taking into account detectable plasma HIV RNA, an antiretroviral regimen that contained two or more agents with good CNS penetration conferred a trend toward lower odds of CSF pleocytosis (OR 0.45, 95% CI 0.18-1.12, p = 0.087). Conclusion: CSF pleocytosis is a characteristic of HIV disease that varies significantly with easily identifiable clinical and laboratory features. Use of antiretroviral agents decreases the odds of pleocytosis. This association may be stronger when the regimen contains two or more agents with good CNS penetration. en_US
dc.description.sponsorship This work was supported by National Institutes of Health grant U54 NS 39406 (AI and CMM). en_US
dc.language.iso en_US en_US
dc.title Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy en_US
dc.type Article en_US


Files in this item

Files Size Format View
1471-2334-7-37.pdf 208.6Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record